MARKER THERAPEUTICS, INC.

Analyst Reco. Marker Therapeutics, Inc.

Equities

MRKR

US57055L2060

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 17:51:22 17/02/2026 GMT			5-day change	1st Jan Change
1.420 ^USD	-0.70%		-8.39%	-4.70%

11-14	Marker Therapeutics Q3 net loss narrows to $2 mln	RE
11-13	Marker Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI

Analyst Reco.

05/03/25	Canaccord Genuity Initiates Marker Therapeutics at Buy With $8 Price Target	MT
30/04/24	Ladenburg Thalmann Starts Marker Therapeutics With Buy Rating, $11 Price Target	MT
31/05/22	Piper Sandler Adjusts Marker Therapeutics' Price Target to $1.50 From $3.50, Reiterates Overweight Rating	MT
17/02/22	Oppenheimer Adjusts Marker Therapeutics' Price Target to $5 From $8, Maintains Outperform Rating	MT
17/02/22	Roth Capital Downgrades Marker Therapeutics to Neutral From Buy, Adjusts Price Target to $1 From $3	MT
25/03/21	MARKER THERAPEUTICS : Piper Sandler Starts Marker Therapeutics at Overweight with $6 Price Target	MT
19/03/21	MARKER THERAPEUTICS : Cantor Fitzgerald Initiates Marker Therapeutics at Overweight Rating With $6 Price Target	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Filters

Rankings

Rankings

Currency / Forex

Commodities

Cryptocurrencies

Interest Rates

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

Unlock them now!